Product Description
VM-1500 is the prodrug of the active compound VM-1500A, a highly selective HIV non-nucleoside reverse transcriptase inhibitor. (Sourced from: https://www.viriom.com/s/5-pharmacokinetics.pdf)
Mechanisms of Action: NNRT Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Viriom
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: HIV Infections
Phase 2: HIV Infections|Acquired Immunodeficiency Syndrome|Deficiency Diseases|Communicable Diseases
Phase 1: HIV Infections|COVID-19
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| HIV-VM1500-10 | P1 |
Completed |
HIV Infections |
2022-07-13 |
60% |
2023-02-24 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
| COVID-VM1500-02 | P1 |
Completed |
HIV Infections|COVID-19 |
2021-08-15 |
2021-12-09 |
Primary Endpoints|Treatments |
|
| HIV-VM1500ALAI-01 | P1 |
Completed |
HIV Infections |
2020-03-27 |
59% |
2021-12-16 |
|
| HIV-VM1500-11 | P1 |
Unknown status |
HIV Infections |
2019-11-01 |
12% |
2021-05-04 |
Primary Endpoints|Treatments|Trial Status |
| HIV-VM1500-09 | P1 |
Completed |
HIV Infections |
2019-04-02 |
2022-01-25 |
||
| VM-1500-002 | P1 |
Completed |
HIV Infections |
2014-10-01 |
2019-03-20 |
Treatments |
|
| 02/HIV/2010 | P1 |
Completed |
HIV Infections |
2013-06-01 |
2019-03-20 |
Treatments |
|
| HIV-VM1500ALAI-02 | P2 |
Completed |
HIV Infections |
2021-08-03 |
2021-12-21 |
Primary Endpoints|Treatments |
|
| VM-1500-001 | P2 |
Completed |
Acquired Immunodeficiency Syndrome|Deficiency Diseases|HIV Infections|Communicable Diseases |
2013-12-01 |
2019-03-20 |
||
| HIV-VM1500ALAI-03 | P3 |
Unknown status |
HIV Infections |
2023-09-30 |
11% |
2024-01-03 |
Primary Endpoints|Treatments|Trial Status |
| HIV-VM1500-04 | P3 |
Completed |
HIV Infections |
2016-04-05 |
2019-03-20 |